Loading
Vaginal dryness and painful sex after cancer treatment are common, lasting and under-treated. Low-dose vaginal oestrogen is the usual answer outside cancer, and for women on an aromatase inhibitor the guidance disagrees: American and British bodies read the same cohort studies differently. A reader deserves to be told that rather than given one confident answer.
Moisturisers and lubricants are first line everywhere, and all the major guidelines say so. The question is what to do when they are not enough.
What is known about absorption. In seven postmenopausal women on aromatase inhibitors, a vaginal oestradiol tablet raised serum oestradiol from 5 picomoles per litre or less to a mean of 72 at two weeks, falling below 35 in most by four weeks; the authors titled the paper a caution and concluded it "is contraindicated". Seven women is a very small basis for a widely quoted conclusion. A randomised placebo-controlled trial of ultra-low-dose 0.005 per cent estriol gel in 61 women on a non-steroidal aromatase inhibitor found it "did not significantly influence estrogens, FSH, and LH levels".
What is known about recurrence. A Danish cohort of 8,461 women found an adjusted relative risk of recurrence with vaginal oestrogen of 1.08 (0.89 to 1.32) overall, but 1.39 (1.04 to 1.85) in the subgroup also taking an aromatase inhibitor, with lower overall mortality in users. A Scottish and Welsh cohort of 49,237 women found no higher breast cancer mortality in users (hazard ratio 0.77, 0.63 to 0.94), but measured mortality rather than recurrence and did not report an aromatase-inhibitor subgroup. A United States claims analysis of 10,584 women with oestrogen-receptor-positive disease found recurrence risk ratio 0.94 (0.77 to 1.15). A 2025 meta-analysis of six observational studies covering 38,050 women on endocrine therapy concluded that in those on an aromatase inhibitor, topical oestrogen "did not increase all-cause mortality" but "may convey an increased risk of recurrence" (relative risk 2.51, 1.10 to 5.72), rated low certainty, and that such a risk "cannot be ruled out".
Where the guidance parts. The American College of Obstetricians and Gynecologists wrote in 2016 that "data do not show an increased risk of cancer recurrence among women currently undergoing treatment for breast cancer or those with a personal history of breast cancer who use vaginal estrogen", with vaginal oestrogen "reserved for those patients who are unresponsive to nonhormonal remedies"; that opinion predates the Danish and British cohorts. The Menopause Society in 2020 said "there are insufficient data at present to confirm the safety of vaginal estrogen or DHEA or ospemifene in women with breast cancer". The British Menopause Society in 2025 is the sharpest: "Neither systemic HRT nor low-dose vaginal estrogen are recommended in women taking an aromatase inhibitor", while "vaginal estrogen can be used in women taking tamoxifen but generally not aromatase inhibitors". ASCO's 2018 guideline keeps it open: lubricants and moisturisers first, and "low-dose vaginal estrogen, lidocaine, and dehydroepiandrosterone may also be considered in some cases".
The non-hormonal alternatives are weaker than their reputation. In a three-arm randomised trial in postmenopausal women, neither a low-dose vaginal oestradiol tablet nor an over-the-counter moisturiser beat placebo gel. Vaginal dehydroepiandrosterone in 464 cancer survivors missed its primary endpoint against plain moisturiser at 12 weeks, though sexual function scores improved. Fractional carbon dioxide laser was no better than sham in a 12-month randomised trial, and it is not funded for this outside research in the United Kingdom.
What comes back, and when: without treatment, it does not. Genitourinary symptoms after an abrupt menopause persist and usually worsen, which is the reason to treat rather than wait. Every option above is a treatment to be continued, not a cure.
Oestrogen maintains vaginal epithelial thickness, glycogen content and the lactobacillus-dominant acidic environment. Withdrawal thins the epithelium and raises pH, producing dryness, fragility, pain and urinary symptoms. A low-dose vaginal preparation aims to restore local tissue without meaningful systemic exposure; in women whose treatment depends on near-complete oestrogen suppression, whether that aim is achieved is the entire question.
Query for this technology: (TITLE:"Vaginal oestrogen after breast cancer: what the evidence says, and where it disagrees" OR ABSTRACT:"Vaginal oestrogen after breast cancer: what the evidence says, and where it disagrees") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Vaginal oestrogen after breast cancer: what the evidence says, and where it disagrees, not a curated reading list.
Shares Anastrozole, Aromatase inhibitor, Menopause brought on by cancer treatment, and the options for it, Exemestane and the tags rejuvenation, survivorship.
Shares Menopause symptoms after chemotherapy for breast cancer, Menopause brought on by cancer treatment, and the options for it, Tamoxifen, Late effects and survivorship toxicity and the tags rejuvenation, survivorship.
Shares Late effects and survivorship toxicity, Survivorship care and late-effects surveillance, Survivorship and late effects are neglected, Endometrial cancer and the tags rejuvenation, survivorship.
Shares Late effects and survivorship toxicity, Survivorship care and late-effects surveillance, Survivorship and late effects are neglected, Toxicity and quality of life are undervalued and the tags rejuvenation, survivorship.
Shares Late effects and survivorship toxicity, Survivorship care and late-effects surveillance, Toxicity and quality of life are undervalued, Triple-negative breast cancer (TNBC) and the tags rejuvenation, survivorship.
Shares Sexual function and intimacy after cancer, for both sexes, Late effects and survivorship toxicity, Survivorship care and late-effects surveillance, Survivorship and late effects are neglected and the tags rejuvenation, survivorship.
Shares Late effects and survivorship toxicity, Survivorship care and late-effects surveillance, Survivorship and late effects are neglected, Toxicity and quality of life are undervalued and the tags rejuvenation, survivorship.
Shares Late effects and survivorship toxicity, Toxicity and quality of life are undervalued, Ovarian cancer, Triple-negative breast cancer (TNBC) and the tags rejuvenation, survivorship.